{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:25:33Z","timestamp":1761845133651},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11899-019-00556-2","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T09:03:40Z","timestamp":1576659820000},"page":"515-522","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)"],"prefix":"10.1007","volume":"14","author":[{"given":"Minas P.","family":"Economides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rizzieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,18]]},"reference":[{"issue":"20","key":"556_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"10","key":"556_CR2","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1182\/blood.V97.10.3210","volume":"97","author":"L Chaperot","year":"2001","unstructured":"Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97(10):3210\u20137.","journal-title":"Blood"},{"issue":"6335","key":"556_CR3","doi-asserted-by":"publisher","first-page":"eaah4573","DOI":"10.1126\/science.aah4573","volume":"356","author":"Alexandra-Chlo\u00e9 Villani","year":"2017","unstructured":"Villani AC, Satija R, Reynolds G, Sarkizova S, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356(6335).","journal-title":"Science"},{"issue":"17","key":"556_CR4","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1182\/blood-2011-03-337501","volume":"118","author":"M Lucioni","year":"2011","unstructured":"Lucioni M, Novara F, Fiandrino G, Riboni R, Fanoni D, Arra M, et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood. 2011;118(17):4591\u20134.","journal-title":"Blood"},{"issue":"10","key":"556_CR5","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/1097-0142(19950515)75:10<2474::AID-CNCR2820751013>3.0.CO;2-Y","volume":"75","author":"JP Brody","year":"1995","unstructured":"Brody JP, Allen S, Schulman P, Sun T, Chan WC, Friedman HD, et al. Acute agranular CD4-positive natural killer cell leukemia. Comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents. Cancer. 1995;75(10):2474\u201383.","journal-title":"Cancer"},{"issue":"2","key":"556_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3324\/haematol.2012.072645","volume":"98","author":"L Pagano","year":"2013","unstructured":"Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239\u201346.","journal-title":"Haematologica"},{"issue":"5","key":"556_CR7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1365-2141.2009.07679.x","volume":"145","author":"F Garnache-Ottou","year":"2009","unstructured":"Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, et al. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624\u201336.","journal-title":"Br J Haematol"},{"issue":"10","key":"556_CR8","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","volume":"14","author":"CT Jordan","year":"2000","unstructured":"Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777\u201384.","journal-title":"Leukemia"},{"issue":"8","key":"556_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/protein\/13.8.575","volume":"13","author":"AE Frankel","year":"2000","unstructured":"Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng. 2000;13(8):575\u201381.","journal-title":"Protein Eng"},{"key":"556_CR10","unstructured":"Therapeutics. S. lzonris (tagraxofusp-erzs): US prescribing information. 2018 6\/9\/2019]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761116s000lbl."},{"issue":"5","key":"556_CR11","first-page":"8204","volume":"8","author":"N Ishibashi","year":"2015","unstructured":"Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Miura K, et al. Radiation therapy for cutaneous blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature. Int J Clin Exp Med. 2015;8(5):8204\u20139.","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"556_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1365-2133.2009.09373.x","volume":"162","author":"S Dalle","year":"2010","unstructured":"Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162(1):74\u20139.","journal-title":"Br J Dermatol"},{"issue":"5","key":"556_CR13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/cncr.21268","volume":"104","author":"R Suzuki","year":"2005","unstructured":"Suzuki R, Nakamura S, Suzumiya J, Ichimura K, Ichikawa M, Ogata K, et al. Blastic natural killer cell lymphoma\/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer. 2005;104(5):1022\u201331.","journal-title":"Cancer"},{"issue":"8","key":"556_CR14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood.2019001144","volume":"134","author":"J Taylor","year":"2019","unstructured":"Taylor J, Haddadin M, Upadhyay VA, Grussie E, Mehta-Shah N, Brunner AM, et al. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019;134(8):678\u201387.","journal-title":"Blood"},{"key":"556_CR15","first-page":"3855","volume":"130","author":"NKHM Pemmaraju","year":"2017","unstructured":"Pemmaraju NKHM, Khoury JD, O\u2019Brien SM, Cortes JE, Garcia-Manero G, Jabbour EJ, et al. Long-term outcomes in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2017;130:3855.","journal-title":"Blood"},{"issue":"6","key":"556_CR16","first-page":"603","volume":"147","author":"A Pileri","year":"2012","unstructured":"Pileri A, Delfino C, Grandi V, Agostinelli C, Pileri SA, Pimpinelli N. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary. G Ital Dermatol Venereol. 2012;147(6):603\u20138.","journal-title":"G Ital Dermatol Venereol"},{"issue":"7","key":"556_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.bmt.1704215","volume":"32","author":"P Reimer","year":"2003","unstructured":"Reimer P, Rudiger T, Kraemer D, Kunzmann V, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637\u201346.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"556_CR18","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.leukres.2009.09.006","volume":"34","author":"NJ Tsagarakis","year":"2010","unstructured":"Tsagarakis NJ, Kentrou NA, Papadimitriou KA, Pagoni M, Kokkini G, Papadaki H, et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic dendritic cell leukemia study group. Leuk Res. 2010;34(4):438\u201346.","journal-title":"Leuk Res"},{"key":"556_CR19","doi-asserted-by":"crossref","unstructured":"Pemmaraju N T D, Kantarjian H, O\u2019Brien SM, Daver NG, Nazha A, Pierce S, Garcia-Manero G, Cortes JE and Faderl S, Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Journal of Clinical Oncology, 2012(30 (Suppl)):6578.","DOI":"10.1200\/jco.2012.30.15_suppl.6578"},{"issue":"4","key":"556_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/107327481402100404","volume":"21","author":"W Riaz","year":"2014","unstructured":"Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014;21(4):279\u201389.","journal-title":"Cancer Control"},{"issue":"22","key":"556_CR21","doi-asserted-by":"publisher","first-page":"19204","DOI":"10.18632\/oncotarget.4146","volume":"6","author":"L Martin-Martin","year":"2015","unstructured":"Martin-Martin L, Lopez A, Vidriales B, Caballero MD, et al. Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget. 2015;6(22):19204\u201316.","journal-title":"Oncotarget"},{"key":"556_CR22","doi-asserted-by":"crossref","unstructured":"Metrus N H R, Ferguson S, Weathers SP, Isolated CNS Blastic Plasmacytoid Dendritic Cell Neoplasm in a Patient with AML (P2.6\u2013014). Neurology, 2019(15 Supplement).","DOI":"10.1212\/WNL.92.15_supplement.P2.6-014"},{"issue":"11","key":"556_CR23","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.3109\/10428194.2016.1160084","volume":"57","author":"R Khwaja","year":"2016","unstructured":"Khwaja R, Daly A, Wong M, Mahe E, et al. Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases. Leuk Lymphoma. 2016;57(11):2720\u20132.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"556_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/ejh.12294","volume":"93","author":"K Laribi","year":"2014","unstructured":"Laribi K, Denizon N, Ghnaya H, Atlassi M, Besan\u00e7on A, Pineau-Vincent F, et al. Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine. Eur J Haematol. 2014;93(1):81\u20135.","journal-title":"Eur J Haematol"},{"issue":"2","key":"556_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s12288-014-0464-3","volume":"31","author":"F Atalay","year":"2015","unstructured":"Atalay F, Demirci GT, Bayramgurler D, Atesoglu EB, et al. Blastic plasmacytoid dendritic cell neoplasm: skin and bone marrow infiltration of three cases and the review of the literature. Indian J Hematol Blood Transfus. 2015;31(2):302\u20136.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"5","key":"556_CR26","doi-asserted-by":"publisher","first-page":"E75","DOI":"10.1002\/ajh.24696","volume":"92","author":"ML Ulrickson","year":"2017","unstructured":"Ulrickson ML, Puri A, Lindstrom S, Cassaday RD, de Padova N, Becker PS. Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2017;92(5):E75\u20137.","journal-title":"Am J Hematol"},{"issue":"3","key":"556_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD DiNardo","year":"2018","unstructured":"\u2022 DiNardo CD, Rausch CR, Benton C, Kadia T, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401\u20137 BCL-2 inhibition in BPDCN.","journal-title":"Am J Hematol"},{"issue":"5","key":"556_CR28","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood.V99.5.1556","volume":"99","author":"J Feuillard","year":"2002","unstructured":"Feuillard J, Jacob MC, Valensi F, Maynadie M, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99(5):1556\u201363.","journal-title":"Blood"},{"issue":"4","key":"556_CR29","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.4081\/rt.2014.5474","volume":"6","author":"H Saeed","year":"2014","unstructured":"Saeed H, Awasthi M, Al-Qaisi A, Massarweh S. Blastic plasmacytoid dendritic cell neoplasm with extensive cutaneous and central nervous system involvement. Rare Tumors. 2014;6(4):5474.","journal-title":"Rare Tumors"},{"issue":"11","key":"556_CR30","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3324\/haematol.2010.026179","volume":"95","author":"AG Jegalian","year":"2010","unstructured":"Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873\u20139.","journal-title":"Haematologica"},{"issue":"17","key":"556_CR31","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"\u2022\u2022 Pemmaraju N, Lane AA, Sweet KL, Stein AS, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628\u201337 Study that led to tagraxofusp approval in BPDCN.","journal-title":"N Engl J Med"},{"issue":"7","key":"556_CR32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.bbmt.2013.01.027","volume":"19","author":"MA Kharfan-Dabaja","year":"2013","unstructured":"Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(7):1006\u201312.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"556_CR33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/bjh.14954","volume":"179","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, et al. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol. 2017;179(5):781\u20139.","journal-title":"Br J Haematol"},{"key":"556_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/01.HS9.0000564424.28977.41","volume":"3","author":"M Qazilbash","year":"2019","unstructured":"Qazilbash M, Bashir Q, Milton D, Patel R, Popat U, Hosing C, et al. Outcomes of autologous and allogeniec hematopoietic stem cell transplanation for BPDCN. Hemasphere. 2019;3:711\u20132.","journal-title":"Hemasphere"},{"issue":"3","key":"556_CR35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","volume":"121","author":"D Roos-Weil","year":"2013","unstructured":"\u2022 Roos-Weil D, Dietrich S, Boumendil A, Polge E, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121(3):440\u20136 SCT in BPDCN. Outcomes from European Cohort.","journal-title":"Blood"},{"issue":"23","key":"556_CR36","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","volume":"125","author":"Tomohiro Aoki","year":"2015","unstructured":"\u2022 Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K., Taguchi J., Kondo T., Ohata K., Ito T., Kamoda Y., Fukuda T., Ichinohe T., Takeuchi K., Izutsu K., Suzumiya J., Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood, 2015. 125(23):3559\u20133562. SCT in BPDCN. Outcomes from American Cohort.","journal-title":"Blood"},{"issue":"4","key":"556_CR37","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1046\/j.1365-2567.1996.493578.x","volume":"87","author":"H Agis","year":"1996","unstructured":"Agis H, Fureder W, Bankl HC, Kundi M, et al. Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Immunology. 1996;87(4):535\u201343.","journal-title":"Immunology"},{"issue":"3","key":"556_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/(SICI)1097-0320(19990301)35:3<249::AID-CYTO8>3.0.CO;2-O","volume":"35","author":"K Toba","year":"1999","unstructured":"Toba K, Koike T, Shibata A, Hashimoto S, Takahashi M, Masuko M, et al. Novel technique for the direct flow cytofluorometric analysis of human basophils in unseparated blood and bone marrow, and the characterization of phenotype and peroxidase of human basophils. Cytometry. 1999;35(3):249\u201359.","journal-title":"Cytometry"},{"issue":"1","key":"556_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2050-7771-2-4","volume":"2","author":"U Testa","year":"2014","unstructured":"Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2(1):4.","journal-title":"Biomark Res"},{"issue":"7","key":"556_CR40","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3324\/haematol.2008.000299","volume":"94","author":"M Djokic","year":"2009","unstructured":"Djokic M, Bjorklund E, Blennow E, Mazur J, et al. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica. 2009;94(7):1016\u20139.","journal-title":"Haematologica"},{"issue":"4","key":"556_CR41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/sj.leu.2401743","volume":"14","author":"AE Frankel","year":"2000","unstructured":"\u2022\u2022 Frankel AE, McCubrey JA, Miller MS, Delatte S, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia. 2000;14(4):576\u201385 Frist study showing tagraxofusp efficacy in BPDCN cell lines.","journal-title":"Leukemia"},{"issue":"3","key":"556_CR42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/10428190701799035","volume":"49","author":"A Frankel","year":"2008","unstructured":"Frankel A, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008;49(3):543\u201353.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"556_CR43","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","volume":"124","author":"AE Frankel","year":"2014","unstructured":"Frankel AE, Woo JH, Ahn C, Pemmaraju N, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385\u201392.","journal-title":"Blood"},{"key":"556_CR44","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1182\/blood.V128.22.2832.2832","volume":"128","author":"S Adams","year":"2016","unstructured":"Adams S, Wilhelm A, Harvey L, Bai C, Yoder N, Kovtun Y, et al. IMGN632: a CD123-targeting antibody-drug conjugate (ADC) with a novel DNA-alkylating payload, is highly active and prolongs survival in acute myeloid leukemia (AML) xenograft models. Blood. 2016;128:2832.","journal-title":"Blood"},{"issue":"Suppl 1","key":"556_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1182\/blood-2018-99-112955","volume":"132","author":"N Daver","year":"2018","unstructured":"Daver N, Erba H, Papadantonakis N, et al. A phase I, first-in-human study evaluating the safety and preliminary anileukemia activity of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed\/refractry acute myeloid luekmia and other CD123-positive hematologic malignancies. Blood. 2018;132(Suppl 1):27.","journal-title":"Blood"},{"issue":"16","key":"556_CR46","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"5","key":"556_CR47","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"key":"556_CR48","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1182\/blood.V128.22.4039.4039","volume":"128","author":"TGR Cai","year":"2016","unstructured":"Cai TGR, Gouble A. Pre-clinical studies of antiCD123 CAR-T cells for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2016;128:4039.","journal-title":"Blood"},{"issue":"S1","key":"556_CR49","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1002\/ajh.25399","volume":"94","author":"W Qasim","year":"2019","unstructured":"Qasim W. Allogeneic CAR T cell therapies for leukemia. Am J Hematol. 2019;94(S1):S50\u20134.","journal-title":"Am J Hematol"},{"key":"556_CR50","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","volume":"130","author":"L Budde","year":"2017","unstructured":"Budde L, Song JY, Kim Y, Blanchard S, Wagner J, Stein AS, et al. Remissions of acute myeloid leukemia and blastic plasmatcytoid dendritic cell neoplasm following treatment with Cd123-specific CAR T cells: a first-in-human clinical trial. Blood. 2017;130:811.","journal-title":"Blood"},{"issue":"2","key":"556_CR51","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","volume":"7","author":"J Montero","year":"2017","unstructured":"Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov. 2017;7(2):156\u201364.","journal-title":"Cancer Discov"},{"issue":"7","key":"556_CR52","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMc1814963","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Konopleva M, Lane AA. More on blastic plasmacytoid dendritic-cell neoplasms. N Engl J Med. 2019;380(7):695\u20136.","journal-title":"N Engl J Med"},{"issue":"24","key":"556_CR53","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1182\/blood-2015-09-671040","volume":"127","author":"A Emadali","year":"2016","unstructured":"Emadali A, Hoghoughi N, Duley S, Hajmirza A, Verhoeyen E, Cosset FL, et al. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. Blood. 2016;127(24):3040\u201353.","journal-title":"Blood"},{"issue":"5","key":"556_CR54","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","volume":"30","author":"M Ceribelli","year":"2016","unstructured":"Ceribelli M, Hou ZE, Kelly PN, Huang DW, Wright G, Ganapathi K, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30(5):764\u201378.","journal-title":"Cancer Cell"},{"issue":"3","key":"556_CR55","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840\u20138.","journal-title":"J Immunol"},{"issue":"3","key":"556_CR56","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384\u201394.","journal-title":"Blood"},{"issue":"9","key":"556_CR57","doi-asserted-by":"publisher","first-page":"e432","DOI":"10.3324\/haematol.2018.214635","volume":"104","author":"KF Iversen","year":"2019","unstructured":"Iversen KF, Holdgaard PC, Preiss B, Nyvold CG, Plesner T. Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report. Haematologica. 2019;104(9):e432\u20133.","journal-title":"Haematologica"},{"issue":"14","key":"556_CR58","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A List","year":"2006","unstructured":"List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456\u201365.","journal-title":"N Engl J Med"},{"key":"556_CR59","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CMAR.S81310","volume":"7","author":"N Ghosh","year":"2015","unstructured":"Ghosh N, Grunwald MR, Fasan O, Bhutani M. Expanding role of lenalidomide in hematologic malignancies. Cancer Manag Res. 2015;7:105\u201319.","journal-title":"Cancer Manag Res"},{"issue":"19","key":"556_CR60","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1158\/1078-0432.CCR-11-0212","volume":"17","author":"A Agliano","year":"2011","unstructured":"Agliano A, Martin-Padura I, Marighetti P, Gregato G, Calleri A, Prior C, et al. Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma\/blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2011;17(19):6163\u201373.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"556_CR61","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/leu.2014.64","volume":"28","author":"MR Sapienza","year":"2014","unstructured":"Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA, et al. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia. 2014;28(8):1606\u201316.","journal-title":"Leukemia"},{"issue":"11","key":"556_CR62","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3324\/haematol.2017.169326","volume":"102","author":"L Philippe","year":"2017","unstructured":"Philippe L, Ceroi A, Bole-Richard E, Jenvrin A, et al. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2017;102(11):1861\u20138.","journal-title":"Haematologica"},{"key":"556_CR63","doi-asserted-by":"crossref","unstructured":"\u2022 Marmouset V, Joris M, Merlusca L, Beaumont M, et al. The lenalidomide\/bortezomib\/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm. Hematol Oncol. 2019; Novel use of combination lenalidomide, bortezomib and dexamethasone in heavily pretreated BPDCN.","DOI":"10.1002\/hon.2671"},{"issue":"6","key":"556_CR64","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00277-019-03623-z","volume":"98","author":"C Yang","year":"2019","unstructured":"Yang C, Fu C, Feng Y, Zhao S, Weng H, Zhang L, et al. Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm. Ann Hematol. 2019;98(6):1525\u20137.","journal-title":"Ann Hematol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00556-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-019-00556-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00556-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T20:23:46Z","timestamp":1722198226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-019-00556-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["556"],"URL":"https:\/\/doi.org\/10.1007\/s11899-019-00556-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"18 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Minas P. Economides declares no conflict of interest.David Rizzieri declares the following: advisory and consultative work with Immunogen, Mustang Bioscience, Stemline; honoraria from Stemline.Naveen Pemmaraju declares the following: consulting\/honorarium from Celgene, Stemline, Incyte Corporation, Novartis, MustangBio, Roche Diagnostics, and LFB. Research funding\/clinical trials support from Stemline, Novartis, Abbvie, Samus, Cellectis, Plexxikon, Daiichi-Sankyo, Affymetrix, and SagerStrong Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}